Ravid M, Greenman Y, Shapira J, Kedar I
Department of Medicine, Meir General Hospital, Kfar Saba, Israel.
Isr J Med Sci. 1990 Apr;26(4):191-4.
Standardization of the measurement of amyloid degrading activity (ADA) by diffusion of serum in amyloid-impregnated agar plates may either indicate or exclude with reasonable certainty the presence of systemic AA amyloidosis. In certain cases, it may obviate the need for a diagnostic biopsy. The sera of 38 patients with systemic amyloidosis were tested and compared with sera of 38 controls matched for age, serum creatinine and albumin blood levels, and with sera of 48 additional controls with the same basic diseases as the amyloidotic patients but without amyloidosis. The difference between ADA of amyloidotic and control patients was significant, with no overlap in the range of activity between the two groups. A positive correlation was found between ADA and serum albumin concentration in the nonamyloidotic matched controls but not in patients with amyloidosis. Our data do not support the view that the decline in ADA of sera of amyloidotic patients is due to hypoalbuminemia.
通过血清在淀粉样蛋白浸渍琼脂平板中的扩散来测定淀粉样蛋白降解活性（ADA）的标准化方法，可能有合理的把握表明或排除全身性AA淀粉样变性的存在。在某些情况下，它可能无需进行诊断性活检。对38例全身性淀粉样变性患者的血清进行了检测，并与38名年龄、血清肌酐和白蛋白血水平相匹配的对照者的血清，以及48名患有与淀粉样变性患者相同基础疾病但无淀粉样变性的额外对照者的血清进行了比较。淀粉样变性患者与对照患者的ADA差异显著，两组之间的活性范围没有重叠。在非淀粉样变性匹配对照中发现ADA与血清白蛋白浓度呈正相关，但在淀粉样变性患者中未发现。我们的数据不支持淀粉样变性患者血清ADA下降是由于低白蛋白血症这一观点。
